14,15-Dihydroxyeicosatrienoic acid activates peroxisome proliferator-activated receptor-α

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 290, Issue 1, 2006, Pages

  Fang, Xiang ^a   Hu, Shanming ^a   Xu, Bingkun ^a   Snyder, Gary D ^a   Harmon, Shawn ^a   Yao, Jianrong ^a   Liu, Yi ^c   Sangras, Bhavani ^d   Falck, J R ^d   Weintraub, Neal L ^a,b   Spector, Arthur A ^a  

^a UNIVERSITY OF IOWA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

14,15 epoxyeicosatrieonic acid analogs; Cytochrome P 450; Soluble epoxide hydrolase

Indexed keywords

14 HEXYLOXYTETRADECENOIC ACID; 14,15 DIHYDROXYEICOSATRIENOIC ACID; 14,15 EPOXY 5,8,11 ICOSATRIENOIC ACID; CARNITINE PALMITOYLTRANSFERASE; DICYCLOHEXYLUREA; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; LUCIFERASE; MYRISTIC ACID DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PIRINIXIC ACID; UNCLASSIFIED DRUG; UREA; 1,3 DICYCLOHEXYLUREA; 1,3-DICYCLOHEXYLUREA; 14,15 EPOXY 5,8,11 EICOSATRIENOIC ACID; 14,15-DIHYDROXYEICOSATRIENOIC ACID; 14,15-EPOXY-5,8,11-EICOSATRIENOIC ACID; ARACHIDONIC ACID DERIVATIVE; DIHOMO GAMMA LINOLENIC ACID; DRUG DERIVATIVE; EPOXIDE;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL LINE; CONTROLLED STUDY; ENZYME ACTIVITY; HEPATOMA CELL; HUMAN; HUMAN CELL; INCUBATION TIME; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; ANIMAL; BIOSYNTHESIS; CELL STRAIN COS1; CERCOPITHECUS; GENETICS; METABOLISM; TUMOR CELL LINE;

8,11,14-EICOSATRIENOIC ACID; ANIMALS; ARACHIDONIC ACIDS; CARNITINE O-PALMITOYLTRANSFERASE; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; EPOXIDE HYDROLASES; EPOXY COMPOUNDS; HUMANS; PPAR ALPHA; UREA;

EID: 33644790290     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00427.2005     Document Type: Article

References (53)

1. Bishop-Bailey D and Wray J. Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation. Prostagl Lipid Mediat 71: 1-22, 2003.
2. Ca channels. Am J Physiol Heart Circ Physiol 282: H1656-H1664, 2002.
3. Campbell WB, Gebremedhin D, Pratt PF, and Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 78: 415-423, 1996.
4. Capdevila JH, Falck JR, and Harris RC. Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. J Lipid Res 41: 163-181, 2000.
5. Catella F, Lawson JA, Fitzgerald DJ, and FitzGerald GA. Endogenous biosynthesis of arachidonic acid epoxides in humans: increased formation in pregnancy-induced hypertension. Proc Natl Acad Sci USA 87: 5893-5897, 1990.
6. Chen P, Hu SM, Yao JR, Moore SA, Spector AA, and Fang X. Induction of cyclooxygenase-2 by anandamide in cerebral microvascular endothelium. Microvasc Res 69: 28-35, 2005.
7. Chinetti G, Lestavel S, Fruchart JC, Clavey V, and Staels B. Peroxisome proliferator-activated receptor α reduces cholesterol esterification in macrophages. Circ Res 92: 212-217, 2003.
8. Corey EJ, Niwa H, and Falck JR. Selective epoxidation of eicosa-cis-5,8,11,14-tetraenoic (arachidonic) acid and eicosa-cis-8,11,14- trienoic acid. J Am Chem Soc 101: 1586-1587, 1979.
9. Cowart LA, Wei S, Hsu MH, Johnson EF, Krishna MU, Falck JR, and Capdevila JH. The CYP4A isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity peroxisome proliferator-activated receptor ligands. J Biol Chem 277: 35105-35112, 2002.
10. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G, and Staels B. Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1. J Biol Chem 274: 32048-32054, 1999.
11. Delerive P, Gervois P, Fruchart JC, and Staels B. Induction of IκBα expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-́ activators. J Biol Chem 275: 36703-36707, 2000.
12. 4-3-ketones. J Org Chem 21: 1547-1549, 1956.
13. Falck JR, Krishna UM, Reddy YK, Kumar PS, Reddy KM, Hittner SB, Deeter C, Sharma KK, Gauthier KM, and Campbell WB. Comparison of vasodilatory properties of 14,15-EET analogs: structural requirements for dilation. Am J Physiol Heart Circ Physiol 284: H337-H349, 2003.
14. Fang X, Hu SM, Watanabe T, Weintraub NL, Snyder GD, Yao JR, Liu Y, Shyy J, Hammock BD, and Spector AA. Activation of peroxisome proliferator-activated receptor α by substituted urea-derived soluble epoxide hydrolase inhibitors. J Pharmacol Exp Ther 314: 260-270, 2005.
15. Fang X, Kaduce TL, Weintraub NL, and Spector AA. Cytochrome P450 metabolites of arachidonic acid: rapid incorporation and hydration of 14,15-epoxyeicosatrienoic acid in arterial smooth muscle cells. Prostaglandins Leukot Essent Fatty Acids 57: 367-371, 1997.
16. Fang X, Kaduce TL, Weintraub NL, Harmon S, Teesch LM, Morisseau C, Thompson DA, Hammock BD, and Spector AA. Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells. Implications for the vascular effects of soluble epoxide hydrolase inhibition. J Biol Chem 276: 14867-14874, 2001.
17. Fang X, Kaduce TL, Weintraub NL, VanRollins M, and Spector AA. Functional implications of newly characterized pathway of 11,12-epoxyeicosatrienoic acid metabolism in arterial smooth muscle. Circ Res 79: 784-793, 1996.
18. Fang X, Moore SA, Stoll LL, Kaduce TL, Rich G, Weintraub NL, and Spector AA. 14,15-Epoxyeicosatrienoic acid inhibits prostaglandin E2 production in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 275: H2113-H2121, 1998.
19. Fang X, VanRollins M, Kaduce TL, and Spector AA. Epoxyeicosatrienoic acid metabolism in arterial smooth muscle cells. J Lipid Res 36: 1236-46, 1995.
20. Fang X, Weintraub NL, McCaw RB, Hu SM, Harmon SD, Rice JB, Hammock BD, and Spector AA. Effect of soluble epoxide hydrolase inhibition on epoxyeicosatrienoic acid metabolism in human blood vessels. Am J Physiol Heart Circ Physiol 287: H2412-H2420, 2004.
21. Fang X, Weintraub NL, and Spector AA. Differences in positional esterification of 14,15-epoxyeicosatrienoic acid in phosphatidylcholine of porcine coronary artery endothelial and smooth muscle cells. Prostaglandins Other Lipid Mediat 71: 33-42, 2003.
22. Fang X, Weintraub NL, Stoll LL, and Spector AA. Epoxyeicosatrienoic acids increase intracellular calcium concentration in vascular smooth muscle cells. Hypertension 34: 1242-1246, 1999.
23. Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, and Busse R. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 401: 493-497, 1999.
24. Fleming I, Fisslthaler B, Michaelis UR, Kiss L, Popp R, and Busse R. The coronary endothelium-derived hyperpolarizing factor (EDHF) stimulates multiple signaling pathways and proliferation in vascular cells. Pflügers Arch 422: 511-518, 2001.
25. Forman BM, Chen J, and Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc Natl Acad Sci USA 94: 4312-4317, 1997.
26. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, and Evans RM. 15-Deoxy-delta 12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 83: 803-812, 1995.
27. Fruchart JC, Duriez P, and Staels B. Peroxisome proliferator-activated receptor-α activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol 10: 245-257, 1999.
28. Han L and Razdan RK. Total synthesis of 2-arachidonylglycerol (2-Ara-Gl). Tetrahedron Lett 40: 1631-1634, 1999.
29. Hirt DL, Capdevila J, Falck JR, Breyer MD, and Jacobson HR. Cytochrome P450 metabolites of arachidonic acid are potent inhibitors of vasopressin action on rabbit cortical collecting duct. J Clin Invest 84: 1805-1812, 1989.
30. Imig JD, Navar LG, Roman RJ, Reddy KK, and Falck JR. Actions of epoxygenase metabolites on the preglomerular vasculature. J Am Soc Nephrol 7: 2364-2370, 1996.
31. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, Devchand P, Wahli W, Willson TM, Lenhard JM, and Lehmann JM. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc Natl Acad Sci USA 94: 4318-4323, 1997.
32. Lee CH, Chawla A, Urbiztondo N, Liao D, Boisvert WA, Evans RM, and Curtiss LK. Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science 302: 453-457, 2003.
33. + channels in isolated rat coronary arterial myocytes. J Physiol 534: 651-667, 2001.
34. Muga SJ, Thuillier P, Pavone A, Rundhaug JE, Boeglin WE, Jisaka M, Brash AR, and Fischer SM. 8S-lipoxygenase products activate peroxisome proliferator-activated receptor alpha and induce differentiation in murine keratinocytes. Cell Growth Differ 11: 447-454, 2000.
35. Murakami K, Ide T, Suzuki M, Mochizuki T, and Kadowaki T. Evidence for direct binding of fatty acids and eicosanoids to human peroxisome proliferators-activated receptor. Biochem Biophys Res Commun 260: 609-613, 1999.
36. Nithipatikom K, Pratt PF, and Campbell WB. Determination of EETs using microbore liquid chromatography with fluorescence detection. Am J Physiol Heart Circ Physiol 279: H857-H862, 2000.
37. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, and Liao JK. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285: 1276-1279, 1999.
38. Oltman CL, Weintraub NL, VanRollins M, and Dellsperger KC. Epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids are potent vasodilators in the canine coronary microcirculation. Circ Res 83: 932-939, 1998.
39. Pfister SL, Falck JR, and Campbell WB. Enhanced synthesis of epoxyeicosatrienoic acids by cholesterol-fed rabbit aorta. Am J Physiol Heart Circ Physiol 261: H843-H852, 1991.
40. Plutzky J. PPARs as therapeutic targets: reverse cardiology? Science 302: 406-407, 2003.
41. Ricote M, Valledor AF, and Glass CK. Decoding transcriptional programs regulated by PPARs and LXRs in the macrophage: effects on lipid homeostasis, inflammation, and atherosclerosis. Arterioscler Thromb Vasc Biol 24: 230-239, 2004.
42. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82:131-185, 2002.
43. Rosolowsky M, Falck JR, Willerson JT, and Campbell WB. Synthesis of lipoxygenase and epoxygenase products of arachidonic acid by normal and stenosed canine coronary arteries. Circ Res 66: 608-621, 1990.
44. Seki K, Hirai A, Noda M, Tamura Y, Kato I, and Yoshida S. Epoxyeicosatrienoic acid stimulates ADP-ribosylation of a 52 kDa protein in rat liver cytosol. Biochem J 281: 185-190, 1992.
45. Spector AA, Fang X, Snyder GD, and Weintraub NL. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog Lipid Res 43: 55-90, 2004.
46. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, and Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators. Nature 393: 790-793, 1998.
47. Sun J, Sui X, Bradbury JA, Zeldin DC, Conte MS, and Liao JK. Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids. Circ Res 90: 1020-1027, 2002.
48. VanRollins M, Kaduce TL, Fang X, Knapp HR, and Spector AA. Arachidonic acid diols produced by cytochrome P-450 monooxygenases are incorporated into phospholipids of vascular endothelial cells. J Biol Chem 271: 14001-14009, 1996.
49. Weintraub NL, Fang X, Kaduce TL, VanRollins M, Chatterjee P, and Spector AA. Potentiation of endothelium-dependent relaxation by epoxyeicosatrienoic acids. Circ Res 81: 258-267, 1997.
50. Yu K, Bayona W, Kallen CB, Harding HP, Ravera CP, McMahon G, Brown M, and Lazar MA. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem 270: 23975-23983, 1995.
51. Yu M, Alonso-Galicia M, Sun CW, Roman RJ, Ono N, Hirano H, Ishimoto T, Reddy YK, Katipally KR, Reddy KM, Gopal VR, Yu J, Takhi M, and Falck JR. 20-Hydroxyeicosatetraenoic acid (20-HETE): structural determinants for renal vasoconstriction. Bioorg Med Chem 11: 2803-21, 2003.
52. Zeldin DC. Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem 276: 36059-36062, 2001.
53. Zhu Y, Schieber EB, McGiff JC, and Balazy M. Identification of arachidonate P-450 metabolites in human platelet phospholipids. Hypertension 25: 854-859, 1995.